MAPK3 and non-small cell lung carcinoma: We have demonstrated here that Shp2 was overexpressed in lung cancer tissue samples from a group of NSCLC patients from Beijing, and that in lung cancer cells, Shp2 promoted proliferation, reduced gefitinib sensitivity, and enhanced migration through activation of the ERK1/2 pathway.